Drug intelligence / Profile preview

Vetasen

Development stage: Unknown
Lead developer: Triman
Modality: Small Molecules
Administration: Oral

Overview

**Vetasen** is an Indonesian fixed-dose oral cough-and-cold tablet marketed by Triman. Each tablet contains guaifenesin 100 mg, dextromethorphan hydrobromide 15 mg, and chlorphenamine maleate 2 mg. Guaifenesin acts as an expectorant to facilitate clearance of respiratory secretions, dextromethorphan is a centrally acting antitussive, and chlorphenamine is a sedating histamine H1-receptor antihistamine that helps relieve allergy-associated upper-respiratory symptoms. The manufacturer indicates Vetasen for relief of cough and cold symptoms. ([triman.co.id](https://triman.co.id/vetasen.html))

Brand names: Vetasen

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Vetasen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vetasen.

Explore the full profile